UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):September 20, 2004
Lifecore Biomedical, Inc.
(Exact name of Registrant as specified in its charter)
| | | | | |
| Minnesota | | O-4136 | | 41-0948334 |
| |
| |
|
(State or other jurisdiction of
incorporation or organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | | |
3515 Lyman Boulevard
| | |
Chaska, Minnesota
| | 55318 |
| |
|
(Address of principal executive
| | (Zip Code) |
offices)
| | |
Registrant’s telephone number, including area code: 952-368-4300
TABLE OF CONTENTS
Item 1.02 Termination of a Material Definitive Agreement
On September 20, 2004, the Company entered into an agreement to terminate its Conveyance, License, Development and Supply Agreement (the “Supply Agreement”) dated August 8, 1994, with Ethicon, Inc., relating to the development, supply and distribution of hyaluronic acid-based products to prevent the formation of surgical adhesions.
Under the terms of the Supply Agreement, Ethicon, through its Gynecare division, distributed a product under the name GYNECARE INTERGEL* Adhesion Prevention Solution prior to March 28, 2003. On March 27, 2003, a voluntary withdrawal of Intergel from the market was initiated in order to assess information obtained during the post-marketing experience with Intergel.
The termination agreement provides for the transfer of worldwide marketing and distribution rights to the Company’s ferric hyaluronan adhesion prevention product from Ethicon to the Company, and further provides that Ethicon will have no responsibility for any aspect of the future manufacture, marketing, sale or distribution of the product nor will it derive any financial benefit therefrom.
A copy of the press release announcing the termination of the Supply Agreement is filed as Exhibit 99.1 hereto.
| * | | Trademark of Ethicon, Inc. |
Item 9.01 Financial Statements and Exhibits
(c) The following exhibit is being furnished herewith:
99.1 Press release dated September 20, 2004
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | LIFECORE BIOMEDICAL, INC.
| |
| Dated: September 23, 2004 | /s/ Dennis J. Allingham | |
| | Dennis J. Allingham | |
| | Chief Executive Officer and President | |
Exhibit Index
| | | |
| 99.1 | | Press release dated September 20, 2004 |
